Ectonucleotidase inhibitors and methods of use thereof

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 11208414
APP PUB NO 20200087310A1
SERIAL NO

16585195

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ANTENGENE THERAPEUTICS LIMITED6/F RFCM MANULIFE PLACE 348 KWUN TONG ROAD KOWLOON HONG KONG

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Billedeau, Roland J Santa Clara, US 15 51
Chen, Lijing Cupertino, US 31 307
Li, Jim San Francisco, US 63 978
Sjogren, Eric B Mountain View, US 39 434

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jun 28, 2025
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 28, 2029
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 28, 2033
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00